{"filing":{"accession_number":"0001213900-26-075199","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-07-06","report_date":null,"primary_document":"ea0297094-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026075199/ea0297094-6k_canfite.htm"},"events":[{"id":16099,"run_id":14366,"accession_number":"0001213900-26-075199","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces completion of patient enrollment (247 patients) in a pivotal Phase 3 clinical trial for Piclidenoson in psoriasis, with interim analysis expected Q4 2026/Q1 2027 under FDA and EMA-agreed protocol. This is a material clinical development milestone for a clinical-stage biotech company, but it is not a discrete event type in the taxonomy (not earnings, M\u0026A, litigation, or a specific financial/governance action). It represents a significant operational/strategic advancement in the company's drug development pipeline that would affect a reasonable investor's assessment of the registrant's progress toward regulatory approval and commercialization.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":[{"id":14077,"accession_number":"0001213900-26-075199","item_number":"EX-99.1","item_title":"ea029709401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of patient enrollment (247 patients) in a pivotal Phase 3 clinical trial for Piclidenoson in psoriasis, with interim analysis expected Q4 2026/Q1 2027 under FDA and EMA-agreed protocol. This is a material clinical development milestone for a clinical-stage biotech company, but it is not a discrete event type in the taxonomy (not earnings, M\u0026A, litigation, or a specific financial/governance action). It represents a significant operational/strategic advancement in the company's drug development pipeline that would affect a reasonable investor's assessment of the registrant's progress toward regulatory approval and commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-06T11:03:37.871679+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14077,"accession_number":"0001213900-26-075199","item_number":"EX-99.1","item_title":"ea029709401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of patient enrollment (247 patients) in a pivotal Phase 3 clinical trial for Piclidenoson in psoriasis, with interim analysis expected Q4 2026/Q1 2027 under FDA and EMA-agreed protocol. This is a material clinical development milestone for a clinical-stage biotech company, but it is not a discrete event type in the taxonomy (not earnings, M\u0026A, litigation, or a specific financial/governance action). It represents a significant operational/strategic advancement in the company's drug development pipeline that would affect a reasonable investor's assessment of the registrant's progress toward regulatory approval and commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-06T11:03:37.871679+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-07-06"}]}